PI19/00808/Instituto de Salud Carlos III[Grants and Funding] - Search Results

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Save citations to file

Email citations

Subject: PI19/00808/Instituto de Salud Carlos III[Grants a - PubMed

To:

From:

Selection:

Format:

MeSH and other data

Add to Collections

Add to My Bibliography

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Results by year

Year	Number of Results
2020	4
2021	7
2022	2
2023	4
2024	3

20 results

Page of 2

Results by year

Page 1

T-reg transcriptomic signatures identify response to check-point inhibitors.

Noblejas-López MDM, García-Gil E, Pérez-Segura P, Pandiella A, Győrffy B, Ocaña A. Noblejas-López MDM, et al. Sci Rep. 2024 May 6;14(1):10396. doi: 10.1038/s41598-024-60819-8. Sci Rep. 2024. PMID: 38710724 Free PMC article.

In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.

Sanvicente A, Díaz-Tejeiro C, Nieto-Jiménez C, Paniagua-Herranz L, López Cade I, Balázs G, Moreno V, Pérez-Segura P, Calvo E, Ocaña A. Sanvicente A, et al. Int J Mol Sci. 2024 Apr 3;25(7):3987. doi: 10.3390/ijms25073987. Int J Mol Sci. 2024. PMID: 38612803 Free PMC article.

Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.

Paniagua-Herranz L, Moreno I, Nieto-Jiménez C, Garcia-Lorenzo E, Díaz-Tejeiro C, Sanvicente A, Doger B, Pedregal M, Ramón J, Bartolomé J, Manzano A, Gyorffy B, Gutierrez-Uzquiza Á, Pérez Segura P, Calvo E, Moreno V, Ocana A. Paniagua-Herranz L, et al. Int J Mol Sci. 2024 Feb 13;25(4):2222. doi: 10.3390/ijms25042222. Int J Mol Sci. 2024. PMID: 38396898 Free PMC article.

Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.

López de Sá A, Díaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jiménez C, Paniagua-Herranz L, Sanvicente A, Calvo E, Pérez-Segura P, Moreno V, Moris F, Ocana A. López de Sá A, et al. J Hematol Oncol. 2023 Dec 12;16(1):118. doi: 10.1186/s13045-023-01519-0. J Hematol Oncol. 2023. PMID: 38087293 Free PMC article. Review.

Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents.

Del Campo-Balguerías A, Parra-Cadenas B, Nieto-Jimenez C, Bravo I, Ripoll C, Poyatos-Racionero E, Gancarski P, Carrillo-Hermosilla F, Alonso-Moreno C, Ocaña A. Del Campo-Balguerías A, et al. Int J Mol Sci. 2023 Sep 7;24(18):13820. doi: 10.3390/ijms241813820. Int J Mol Sci. 2023. PMID: 37762123 Free PMC article.

Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.

Nieto-Jiménez C, Sanvicente A, Díaz-Tejeiro C, Moreno V, Lopez de Sá A, Calvo E, Martínez-López J, Pérez-Segura P, Ocaña A. Nieto-Jiménez C, et al. Clin Transl Med. 2023 Sep;13(9):e1329. doi: 10.1002/ctm2.1329. Clin Transl Med. 2023. PMID: 37740463 Free PMC article. Review.

Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities.

Paniagua-Herranz L, Doger B, Díaz-Tejeiro C, Sanvicente A, Nieto-Jiménez C, Moreno V, Pérez Segura P, Gyorffy B, Calvo E, Ocana A. Paniagua-Herranz L, et al. Cancers (Basel). 2023 Jun 20;15(12):3250. doi: 10.3390/cancers15123250. Cancers (Basel). 2023. PMID: 37370859 Free PMC article.

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.

Juan A, Noblejas-López MDM, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A. Juan A, et al. Cancers (Basel). 2022 Sep 15;14(18):4474. doi: 10.3390/cancers14184474. Cancers (Basel). 2022. PMID: 36139634 Free PMC article.

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.

Noblejas-López MDM, Gandullo-Sánchez L, Galán-Moya EM, López-Rosa R, Tébar-García D, Nieto-Jiménez C, Gómez-Juárez M, Burgos M, Pandiella A, Ocaña A. Noblejas-López MDM, et al. Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476. Int J Mol Sci. 2022. PMID: 35628286 Free PMC article.

Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer.

Domínguez-Jurado E, Cimas FJ, Castro-Osma JA, Juan A, Lara-Sánchez A, Rodríguez-Diéguez A, Shafir A, Ocaña A, Alonso-Moreno C. Domínguez-Jurado E, et al. Pharmaceutics. 2021 Sep 26;13(10):1559. doi: 10.3390/pharmaceutics13101559. Pharmaceutics. 2021. PMID: 34683852 Free PMC article.

20 results

Page of 2

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

20 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year